Lexaria Bioscience Corp

NASDAQ:LEXX

0.74

-0.03 (-3.80%)

4:28:55 PM EDT: $0.73 -0.01 (-1.80%)

Market Cap (Intraday)	6.02M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.14 Million
Adjusted EPS	-$0.28

See more estimates

10-Day MA	$0.77
50-Day MA	$1.51
200-Day MA	$2.37

See more pivots

Lexaria Bioscience Corp Stock, NASDAQ:LEXX

740 McCurdy Road, Suite 100, Kelowna, British Columbia V1X 2P7

United States of America

Phone: +1.250.765.6424

Number of Employees: 7

http://www.lexariabioscience.com

Description

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs encompassing fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.